- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05493904
PREcise Percutaneous Coronary Intervention for Stent OptimizatION in Treatment of COMPLEX Lesion (PRECISION-COMPLEX)
Impact of Optical Coherence Tomography-guided Versus Angiography-guided Stent Optimization on Post-Interventional Fractional Flow Reserve in Patients With Complex Coronary Artery Lesions
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
There has been ample evidence of the role of intracoronary imaging for optimizing the stent, especially among the patients with complex coronary lesions. Intracoronary imaging can be used during the entire process of percutaneous coronary intervention (PCI), from pre-PCI to post-PCI stages. Notably, approximately 15-20% of patients who underwent angiographically successful PCI showed significant stent underexpansion, malapposition, intra-stent thrombus formation, and edge dissection on intracoronary imaging studies, including optical coherence tomography (OCT).
Meanwhile, the role of pre-interventional fractional flow reserve (FFR) measurement has been well established and recommended by recent guideline. However, although previous studies evaluated the efficacy and safety of FFR-guided decision-making followed by angiographic stent implantation, they did not evaluate functionally optimized revascularization. Actually, the vessels with low post-PCI FFR had substantial proportions of suboptimized stented (underexpansion and acute malapposition) and residual disease in non-stented segments. Furthermore, several large observational studies have suggested that suboptimal physiologic results after PCI is associated with an increased risk of clinical events. Previously, the DOCTORS trial found out that OCT-guided PCI was associated with higher post-PCI FFR than angiography-guided PCI (0.94±0.04 vs. 0.92±0.05, P=0.005).
Therefore, OCT can be a useful tool for acquiring functional optimal results after stent implantation. This synergic effect between OCT and post-PCI FFR can be maximized when the investigators perform PCI for complex lesions. This study sought to evaluate compare post-interventional FFR value between OCT-guided and angiography-guided strategy for treatment of complex coronary lesion.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Youngkeun Ahn, MD, PhD
- Phone Number: +82-62-220-4764
- Email: cecilyk@hanmail.net
Study Contact Backup
- Name: Seung Hun Lee, MD, PhD
- Phone Number: +82-10-6413-7449
- Email: lsh8602@naver.com
Study Locations
-
-
-
Daegu, Korea, Republic of
- Not yet recruiting
- Keimyung University Dongsan Hospital
-
Contact:
- Chang-Wook Nam, MD, PhD
- Email: namcwcv@gmail.com
-
Principal Investigator:
- Chang-Wook Nam, MD, PhD
-
Gwangju, Korea, Republic of, 61469
- Recruiting
- Chonnam National University Hospital
-
Contact:
- Youngkeun Ahn, MD, PhD
- Phone Number: 82-62-220-5778
- Email: cecilyk@hanmail.net
-
Principal Investigator:
- Youngkeun Ahn, MD, PhD
-
Sub-Investigator:
- Seung Hun Lee, MD, PhD
-
Contact:
- Seung Hun Lee, MD, PhD
- Phone Number: 82-62-220-4246
- Email: lsh8602@naver.com
-
Sub-Investigator:
- Min Chul Kim, MD, PhD
-
Sub-Investigator:
- Joon Ho Ahn, MD, PhD
-
Sub-Investigator:
- Young Joon Hong, MD, PhD
-
Gwangmyeong, Korea, Republic of
- Not yet recruiting
- Chung-Ang University Gwangmyeong Hospital
-
Contact:
- Sang Yeob Lee, MD, PhD
- Email: louisahj@gmail.com
-
Principal Investigator:
- Sang Yeob Lee, MD, PhD
-
Jeju, Korea, Republic of
- Not yet recruiting
- Jeju National University Hospital
-
Contact:
- Song Yi Kim, MD, PhD
- Email: ttoromom@jejunu.ac.kr
-
Principal Investigator:
- Song Yi Kim, MD, PhD
-
Seoul, Korea, Republic of
- Recruiting
- Seoul National University Hospital
-
Contact:
- Bon-Kwon Koo, MD, PhD
- Email: bkkoo@snu.ac.kr
-
Sub-Investigator:
- Doyeon Hwang, MD
-
Principal Investigator:
- Bon-Kwon Koo, MD, PhD
-
Seoul, Korea, Republic of
- Recruiting
- Samsung Medical Center
-
Contact:
- Joo Myung Lee, MD, PhD
- Email: drone80@hanmail.net
-
Sub-Investigator:
- Ki Hong Choi, MD, PhD
-
Principal Investigator:
- Joo Myung Lee, MD, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients >18 years old
- Patients with stable or unstable angina and complex coronary lesions*
Patients who were indicated revascularization
- Diameter stenosis >90% by angiography
- Diameter stenosis with 50~90% with pre-interventional FFR ≤0.80
Patients who underwent implantation of 2nd generation drug-eluting stent
Definitions of complex coronary lesions
- True bifurcation lesion (Medina 1,1,1/1,0,1/0,1,1) with side branch ≥2.5mm size
- Chronic total occlusion (≥3 months) as target lesion
- PCI for unprotected left main (LM) disease (LM os, body, distal LM bifurcation including non-true bifurcation)
- Long coronary lesions (implanted stent ≥38 mm in length)
- Multi-vessel PCI (≥2 major epicardial coronary arteries treated at one PCI session)
- Multiple stents needed (≥3 more stent per patient)
- In-stent restenosis lesion as target lesion
- Severely calcified lesion (encircling calcium in angiography)
- Left anterior descending (LAD), left circumflex artery (LCX), and right coronary artery (RCA) ostial lesion
Exclusion Criteria:
- Target lesions not amenable for PCI by operators' decision
- Cardiogenic shock (Killip class IV) at presentation
- Less than TIMI 3 flow of target vessel after index procedure
- Intolerance to Aspirin, Clopidogrel, Prasugrel, Ticagrelor, Heparin, Everolimus, Zotarolimus, Biolimus, or Sirolimus
- Known true anaphylaxis to contrast medium (not allergic reaction but anaphylactic shock)
- Renal insufficiency such that an additional contrast medium would be harmful for patient
- Recent ST-segment elevation myocardial infarction (STEMI)
- Inability to receive adenosine or nicorandil injection
- Pregnancy or breast feeding
- Non-cardiac co-morbid conditions are present with life expectancy <2 year or that may result in protocol non-compliance (per site investigator's medical judgment)
- Unwillingness or inability to comply with the procedures described in this protocol
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: OCT-guided PCI arm
Use of OCT will be strongly recommended at any step of PCI (pre-PCI, during PCI and post-PCI), but OCT evaluation after stent implantation will be mandatory.
In case of staged procedure during the same hospitalization, following the initially allocated strategy would be strongly recommended.
|
For patients randomly allocated to this arm, PCI for complex lesions will be performed using OCT. OCT Reference site: Most normal looking segment, No Lipidic plaque. Operator can decide 1 of 2 methods for stent sizing.
All patient will be received percutaneous coronary intervention with second generation drug-eluting stent.
|
Active Comparator: Angiography-guided PCI arm
The PCI procedure in this group will be performed as standard procedure.
After deployment of stent, stent optimization will be done based on angiographic findings.
In case of staged procedure during the same hospitalization, following the initially allocated strategy would be strongly recommended.
|
All patient will be received percutaneous coronary intervention with second generation drug-eluting stent.
For patients randomly allocated to this arm, PCI for complex lesions will be performed using angiography only. The optimization guided by angiography should meet the criteria of angiographic residual diameter stenosis less than 30% by visual estimation and the absence of flow limiting dissection (≥Type C dissection). When angiographic under-expansion of the stent is suspected, adjunctive balloon dilatation will be strongly recommended. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Suboptimal post-PCI physiological results
Time Frame: Immediate after the index procedure
|
Proportion of patients with a final post-interventional fractional flow reserve <0.85
|
Immediate after the index procedure
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of target vessel failure (TVF)
Time Frame: 2-Year after the index procedure
|
a composite of cardiac death, target-vessel myocardial infarction (MI), and target-vessel revascularization (TVR)
|
2-Year after the index procedure
|
Rate of all-cause death
Time Frame: 2-Year after the index procedure
|
death from any-cause
|
2-Year after the index procedure
|
Rate of cardiac death
Time Frame: 2-Year after the index procedure
|
death from cardiac-cause
|
2-Year after the index procedure
|
Rate of target vessel MI without periprocedural MI
Time Frame: 2-Year after the index procedure
|
Myocardial infarction without periprocedural myocardial infarction
|
2-Year after the index procedure
|
Rate of target vessel MI with periprocedural MI
Time Frame: 2-Year after the index procedure
|
Myocardial infarction with periprocedural myocardial infarction
|
2-Year after the index procedure
|
Rate of target lesion revascularization (TLR)
Time Frame: 2-Year after the index procedure
|
ischemia-driven or all
|
2-Year after the index procedure
|
Rate of target vessel revascularization (TVR)
Time Frame: 2-Year after the index procedure
|
ischemia-driven or all
|
2-Year after the index procedure
|
Rate of any MI
Time Frame: 2-Year after the index procedure
|
any myocardial infarction
|
2-Year after the index procedure
|
Rate of any revascularization
Time Frame: 2-Year after the index procedure
|
ischemia-driven or all
|
2-Year after the index procedure
|
Rate of stent thrombosis
Time Frame: 2-Year after the index procedure
|
definite, probable, or possible
|
2-Year after the index procedure
|
FFR gain between pre- and post-interventional stages
Time Frame: Immediate after the index procedure
|
[Post-interventional fractional flow reserve value] - [Pre-interventional fractional flow reserve value]
|
Immediate after the index procedure
|
Trans-stent FFR gradient
Time Frame: Immediate after the index procedure
|
FFR gradient across the stent (ΔFFRstent)
|
Immediate after the index procedure
|
Post-interventional non-hyperemic pressure ratios
Time Frame: Immediate after the index procedure
|
Values of post-PCI non-hyperemic pressure ratios
|
Immediate after the index procedure
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of contrast-induced nephropathy
Time Frame: 48-72 hours after index procedure
|
defined as an increase in serum creatinine of ≥0.5mg/dL or ≥25% from baseline after contrast agent exposure
|
48-72 hours after index procedure
|
Total procedure time
Time Frame: Immediate after the index procedure
|
Total procedure time
|
Immediate after the index procedure
|
Total amount of contrast dose
Time Frame: Immediate after the index procedure
|
Total amount of contrast dose
|
Immediate after the index procedure
|
Total fluoroscopy time
Time Frame: Immediate after the index procedure
|
Total fluoroscopy time
|
Immediate after the index procedure
|
Total amount of radiation dose
Time Frame: Immediate after the index procedure
|
Total amount of radiation dose
|
Immediate after the index procedure
|
Collaborators and Investigators
Collaborators
Investigators
- Study Chair: Youngkeun Ahn, MD, PhD, Chonnam National University Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CNUH-2022-283
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Artery Disease
-
Elixir Medical CorporationIstituto Clinico HumanitasActive, not recruitingCoronary Artery Disease | Chronic Total Occlusion of Coronary Artery | Multi Vessel Coronary Artery Disease | Bifurcation of Coronary Artery | Long Lesions Coronary Artery DiseaseItaly
-
Fundación EPICActive, not recruitingCoronary Artery Disease | Left Main Coronary Artery Disease | Left Main Coronary Artery Stenosis | Restenosis, CoronarySpain
-
Peking Union Medical College HospitalNot yet recruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Peking Union Medical College HospitalRecruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
IGLESIAS Juan FernandoUniversity of BernNot yet recruiting
-
Barts & The London NHS TrustImperial College London; Brunel UniversityNot yet recruitingCORONARY ARTERY DISEASE
-
National Institutes of Health Clinical Center (CC)National Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Arteriosclerosis | Coronary Artery Disease (CAD) | Obstructive Coronary Artery DiseaseUnited States
-
Fundación EPICRecruitingCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Left Main Coronary Artery Disease | Coronary Artery StenosisSpain
-
Abbott Medical DevicesCompletedCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Chronic Total Occlusion of Coronary Artery | Coronary Restenosis | Coronary Artery Stenosis | Coronary Artery RestenosisBelgium
-
China National Center for Cardiovascular DiseasesRecruitingLeft Main Coronary Artery DiseaseChina
Clinical Trials on OCT-guided PCI
-
Odense University HospitalActive, not recruitingMyocardial Infarction | Coronary Artery DiseaseDenmark
-
Catholic University of the Sacred HeartUnknownIschemic Heart DiseaseItaly
-
Yonsei UniversityCompletedCoronary Artery DiseaseKorea, Republic of
-
University Hospital Inselspital, BerneTerminated
-
Careggi HospitalCompletedCoronary Artery | Stent Thrombosis | Platelet | ThrombusItaly
-
Aarhus University Hospital SkejbyAbbottActive, not recruitingIschemic Heart Disease | Ischaemic Heart DiseaseDenmark, United Kingdom, Sweden, Finland, Germany, Belgium, Norway, Poland, Netherlands, Estonia, Ireland, Italy, Latvia
-
Assiut UniversityWakayama Medical UniversityCompleted
-
Harbin Medical UniversityNot yet recruitingIntravascular Imaging and Microvascular Obstruction
-
Abbott Medical DevicesAbbottCompletedCoronary Artery Disease | Atherosclerosis | Coronary Stenosis | STEMI | NSTEMI - Non-ST Segment Elevation MI | STEMI - ST Elevation Myocardial InfarctionUnited States, Spain, Australia, United Kingdom, Canada, New Zealand, Denmark, Switzerland, Germany, Netherlands, India, Japan, Italy, Belgium, France, Hong Kong, Portugal, Singapore, Sweden, Taiwan
-
Abbott Medical DevicesCardiovascular Research Foundation, New YorkCompletedCoronary Artery DiseaseUnited States, Spain, Japan, United Kingdom, Germany, Belgium, Italy, Netherlands